Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance

被引：27

作者：

de Mendoza, C ^{[1
]}

Valer, L

Bacheler, L

Pattery, T

Corral, A

Soriano, V

机构：

[1] Hosp Carlos 3, Infect Dis Serv, Madrid, Spain

[2] VircoLab Inc, Durham, NC USA

[3] Virco BVBA, Mechelen, Belgium

来源：

AIDS | 2006年 / 20卷 / 07期

关键词：

D O I：

10.1097/01.aids.0000222084.44411.cc

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Mutation proI47A has recently been associated with lopinavir/ritonavir (LPV/r) resistance. Only four out of 1859 specimens (0.2%) sent for drug resistance testing (219 drug-naive and 1650 antiretroviral-experienced) showed I47A. All belonged to patients failing LPV/r. The prevalence among protease inhibitor-experienced patients was 0.6%. Phenotypic testing showed that proI47A caused high-level lopinavir resistance (> 100-fold) and cross-resistance to amprenavir, whereas it caused hypersusceptibility to saquinavir. ProI47A should thus be considered the primary lopinavir resistance mutation.

引用

收藏

页码：1071 / 1073

页数：3

相关论文

共 20 条

[1]

Bongiovanni M, 2003, ANTIVIR THER, V8, P209

[2] Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR Study) [J].

Breilh, D ;

Pellegrin, I ;

Rouzés, A ;

Berthoin, K ;

Xuereb, F ;

Budzinski, H ;

Munck, M ;

Fleury, HJA ;

Saux, MC ;

Pellegrin, JL .

AIDS, 2004, 18 (09) :1305-1310

[3] In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor [J].

Carrillo, A ;

Stewart, KD ;

Sham, HL ;

Norbeck, DW ;

Kohlbrenner, WE ;

Leonard, JM ;

Kempf, DJ ;

Molla, A .

JOURNAL OF VIROLOGY, 1998, 72 (09) :7532-7541

[4] Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an aintiretroviral-naive patient [J].

Conradie, F ;

Sanne, I ;

Venter, W ;

Eron, J .

AIDS, 2004, 18 (07) :1084-1085

[5]

de Mendoza Carmen, 2002, HIV Clin Trials, V3, P304

[6] Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient [J].

de Requena, DG ;

Gallego, O ;

Valer, L ;

Jiménez-Nácher, I ;

Soriano, V .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 2004, 20 (03) :275-278

[7] Once-daily versus twice-daily Lopinavir/Ritonavir in antiretroviral-naive HIV-positive patients: A 48-week randomized clinical trial [J].

Eron, JJ ;

Feinberg, J ;

Kessler, HA ;

Horowitz, HW ;

Witt, MD ;

Carpio, FF ;

Wheeler, DA ;

Ruane, P ;

Mildvan, D ;

Yangco, BG ;

Bertz, R ;

Bernstein, B ;

King, MS ;

Sun, E .

JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (02) :265-272

[8] Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen [J].

Friend, J ;

Parkin, N ;

Liegler, T ;

Martin, JN ;

Deeks, SG .

AIDS, 2004, 18 (14) :1965-1966

[9] Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type β-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp. -: J Antimicrob Chemother 1998; 42:269-270 [J].

Vahaboglu, H ;

Saribas, S ;

Akbal, H ;

Ozturk, R ;

Yucel, A .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (02) :269-270

[10] Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study [J].

Hicks, C ;

King, MS ;

Gulick, RA ;

White, AC ;

Eron, JJ ;

Kessler, HA ;

Benson, C ;

King, KR ;

Murphy, RL ;

Brun, SC .

AIDS, 2004, 18 (05) :775-779